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Abnormalities in the kynurenine pathway are associatedwith neurodegenerative disorders. Zwilling
et al. (2011) show that inhibition of kynurenine 3-monooxygenase in the body’s periphery leads to an
increase in kyneuric acid, a neuroprotective compound, in the brain. This intervention ameliorates
neurodegeneration in mouse models of Alzheimer’s disease and Huntington’s disease.One of the cellular pathways previously
linked to neurodegenerative diseases, in-
cluding Alzheimer’s disease (AD) (Jacob-
sen et al., 2005) and Huntington’s disease
(HD) (Crook and Housman, 2011), is the
kynurenine pathway of tryptophan degra-
dation (Figure 1; Stone and Darlington,
2002; Schwarcz, 2004), the most impor-
tant route of tryptophan catabolism in hu-
mans. Two metabolites in this pathway
are elevated in the blood and brains of
AD and HD patients: quinolinic acid is
associated with glutamate receptor ex-
citotoxicity, and 3-hydroxykynurenine is
associated with free radical generation.
In contrast, the concentration of kynurenic
acid, which is thought to be neuroprotec-
tive, is often decreased in AD and HD.
These observations serve as the basis
of a new strategy of therapeutic interven-
tion described in this issue ofCell. Zwilling
et al. (2011) show that the sustained inhi-
bition of kynurenine 3-monooxygenase,
the enzyme catalyzing the conversion of
kynurenine to 3-hydroxykynurenine, ap-
pears to reverse a number of cognitive
and motor deficits measured in AD and
HD mouse models. Inhibiting this enzyme
has the effect of elevating neuroprotective
kynurenic acid levels while decreasing the
levels of neurotoxic quinolinic acid and
3-hydroxykynurenine.
There are two interesting twists to this
story. Inhibition of peripheral kynurenine
3-monooxygenase gives rise to an in-
crease in peripheral kynurenine, which is
efficiently transported to the brain, where
it is rapidly converted to the neuroprotec-tive metabolite kynurenic acid. Hence, the
first twist is that inhibition of a peripheral
enzyme translates into the elevation of
a neuroprotective molecule in brain. Sol-
uble enzyme inhibition in the periphery is
a proven therapeutic strategy employed
by the pharmaceutical industry to treat
a spectrum of diseases.
The second twist to this story is that
the synthesis of a newprodrug, referred to
as JM6, gives rise to the sustained release
of a previously characterized kynurenine
3-monooxygenase inhibitor, Ro 61-8048
(Doody et al., 2011). This prodrug ap-
proach was developed to overcome me-
tabolic instability.
Further raising interest in the same
metabolic pathway, Giorgini and col-
leagues (Campesan et al., 2011, recently
published in Current Biology) provide
persuasive genetic and pharmacological
evidence that inhibition of kynurenine
3-monooxygenase, or tryptophan 2,3-di-
oxygenase, the most upstream trypto-
phan degrading enzyme, is neuroprotec-
tive in a fruit fly model of HD. This
efficacy appears to be linked to an in-
crease in the neuroprotective metabolite
kynurenic acid relative to 3-hydroxykynur-
enine. Furthermore, these authors dem-
onstrate that simply feeding kynurenic
acid to HD model flies protects them
fromneurodegeneration, whereas feeding
3-hydroxykynurenine exacerbates cyto-
toxicity.
Though it is likely that multiple defi-
ciencies act together to cause neurode-
generation and that mechanistically dis-Cell 1tinct drugs will ultimately be required to
halt the progression of neurodegenerative
diseases, the kynurenine 3-monooxy-
genase inhibition strategy is promising
because it offers the potential to alleviate
more thanoneneurodegenerativedisease.
This is particularly appealing because of
the difficulty in conducting successful clin-
ical trials in diseases like AD (Ro¨ver et al.,
1997). Thus, an agent that proves useful
in multiple maladies could be discovered
by an initial trial in a disorder like Hunting-
ton’s disease, wherein the cause—an
autosomal dominant mutation in the hun-
tingtin protein—is much better under-
stood, and disease progression in placebo
controls is better characterized.
Interestingly, JM6 and Ro 61-8048 do
not enter the brain at appreciable concen-
trations. This finding could prove to be
useful for maximizing clinical benefit and
managing toxicity in combination thera-
pies for the treatment of neurodegenera-
tive disease. Because most current thera-
peutic approaches select compounds for
preferential brain exposure, compounds
that function by a peripheral mechanism
may be desirable combination partners.
In transgenic mice overexpressing
amyloid precursor protein, JM6 can im-
prove behavioral endpoints in spatial
memory assays and anxiety assays. That
JM6 has no obvious effects on plaque
size and number raises interesting ques-
tions that merit further investigation. For
example, is thereany intersectionbetween
kynurenine 3-monooxygenase inhibition
and the amyloid cascade, say at the level45, June 10, 2011 ª2011 Elsevier Inc. 813
Figure 1. The Kynurenine Pathway and Neurodegeneration
The kynurenine pathway of tryptophan degradation is the most important route of tryptophan catabolism
in humans. Some metabolites within this pathway are elevated in blood and in the brains of patients with
Alzheimer’s disease or Huntington’s disease. Specifically, there are elevations in quinolinic acid, which is
associatedwith glutamate receptor excitotoxicity, and 3-hydroxykynurenine, which is linked to free radical
generation. In contrast, the concentration of kynurenic acid, thought to be neuroprotective, is decreased.
Drosophila do not synthesize quinolinic acid, the final product of tryptophan degradation in the human
kynurenine pathway. Photomicrographs are from Usui et al. (2009).of Ab oligomers, or is this a completely
independent mechanism? Does kynure-
nine 3-monooxygenase inhibition intersect
with Tau pathology? What are the molec-
ular mechanisms downstream of kynur-
enic acid elevation? Are the enhanced life
span endpoints that are measured in HD814 Cell 145, June 10, 2011 ª2011 Elsevier Inmodels also independent of huntingtin
inclusions?
A number of questions defining the rela-
tionship between the drug’s pharmacoki-
netics and pharmacodynamics remain
to be elaborated. What is the minimal
elevation in kynurenic acid that has thera-c.peutic benefit? The authors have shown
efficacy following chronic dosing for
4 months. How long does the inhibition
of kynurenine 3-monooxygenase need to
be sustained? Lastly, is this treatment
approach prophylactic, or is it efficacious
in animals that are already suffering from
HD aggregates and the associated
behavioral deficits?
These innovative studies and previous
results suggest that decreasing the ratio
of 3-hydroxykynurenine and quinolinic
acid to kynurenic acid using small-mole-
cule inhibitors could be used to treat AD
and HD. As is often the case with new
data that force us to re-evaluate what
we know about disease progression and
intervention, these studies also raise
many new questions, in addition to pro-
viding hope to patients with these mal-
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